| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/10/2011 | CA2418815C Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 05/10/2011 | CA2417806C New immunoeffector compounds |
| 05/10/2011 | CA2416293C Somatostatin analogues |
| 05/10/2011 | CA2411056C Pharmaceutical compositions containing prostacyclin synthase gene |
| 05/10/2011 | CA2406664C Systemic delivery of neural stem cells to treat cancer |
| 05/10/2011 | CA2399866C Compositions and methods for treatment of angiogenesis in pathological lesions |
| 05/10/2011 | CA2387576C Immuno-interactive fragments of the .alpha.c subunit of inhibin |
| 05/10/2011 | CA2382560C Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 05/10/2011 | CA2304810C Tie receptor tyrosine kinase ligand homologues |
| 05/10/2011 | CA2171589C Phosphonomonoester nucleic acids, process for their preparation, and their use |
| 05/05/2011 | WO2011054007A1 Ror1 as therapeutic and diagnostic target |
| 05/05/2011 | WO2011054001A2 Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| 05/05/2011 | WO2011053991A2 Vault complexes for cytokine delivery |
| 05/05/2011 | WO2011053821A1 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| 05/05/2011 | WO2011053750A2 Drug resistant immunotherapy for treatment of a cancer |
| 05/05/2011 | WO2011053660A2 Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors |
| 05/05/2011 | WO2011053618A2 Hydroxyl-terminated dendrimers |
| 05/05/2011 | WO2011053571A1 Phytoestrogenic formulations for alleviation or prevention of hair loss |
| 05/05/2011 | WO2011053476A1 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition |
| 05/05/2011 | WO2011053322A1 Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| 05/05/2011 | WO2011053321A1 Use of autologous effector cells for treatment of multiple myeloma |
| 05/05/2011 | WO2011053223A1 Method for proliferation of antigen-specific t cells |
| 05/05/2011 | WO2011052923A2 Novel 1,6-disubstituted indole compounds as protein kinase inhibitors |
| 05/05/2011 | WO2011052919A2 Novel alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition for an immune adjuvant, containing the derivatives as active ingredients |
| 05/05/2011 | WO2011052883A2 Method for activating a natural killer cell by adjusting the expression of the socs2 gene |
| 05/05/2011 | WO2011052846A1 Pharmaceutical composition containing extracts of native plants as active ingredients for preventing or treating cancer |
| 05/05/2011 | WO2011052753A1 Antibody binding to mansc1 protein and having anticancer activity |
| 05/05/2011 | WO2011052750A1 Anticancer agent sensitivity-determining marker |
| 05/05/2011 | WO2011052749A1 Method for determination of sensitivity to anti-cancer agent |
| 05/05/2011 | WO2011052748A1 Method for determining sensitivity to an anticancer agent |
| 05/05/2011 | WO2011052554A1 Novel 5-fluorouracil derivative |
| 05/05/2011 | WO2011051950A1 9-aminoacridine derivatives, their preparation and uses |
| 05/05/2011 | WO2011051938A1 Composition for treatment of thyroid cancer with fts and analogs thereof |
| 05/05/2011 | WO2011051894A1 Novel antitumoral use of cabazitaxel |
| 05/05/2011 | WO2011051667A1 Targeted dendrimers |
| 05/05/2011 | WO2011051665A1 Anti-cancer composition comprising alginate |
| 05/05/2011 | WO2011051540A1 Androgen receptor modulating compounds |
| 05/05/2011 | WO2011051520A1 Triterpenic saponins from the crocus sativus corm as an adjuvant in protein vaccine formulations |
| 05/05/2011 | WO2011051452A1 N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| 05/05/2011 | WO2011051425A1 N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea |
| 05/05/2011 | WO2011050739A1 Submicro emulsion of paclitaxel using steroid complex as intermediate carrier |
| 05/05/2011 | WO2011050735A1 Paclitaxel/steroidal complex |
| 05/05/2011 | WO2011050710A1 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| 05/05/2011 | WO2011050684A1 Pharmaceutical composition for treating tumor |
| 05/05/2011 | WO2011050575A1 Hydroxy-substituted gold(iii) porphyrin complexes as histone deacetylase inhibitors |
| 05/05/2011 | WO2011050574A1 Pharmaceutical composition containing cyclometalated n-heterocyclic carbene complexes for cancer treatment |
| 05/05/2011 | WO2011031974A9 Acridine analogs in the treatment of gliomas |
| 05/05/2011 | WO2011029980A8 Therapeutic compositions for the treatment of hpv-induced diseases |
| 05/05/2011 | WO2011029639A3 Compounds and methods for treating neoplasia |
| 05/05/2011 | WO2011025938A3 Raf inhibitor compounds and methods of use thereof |
| 05/05/2011 | WO2011006886A3 Azole derivatives as agricultural fungicides |
| 05/05/2011 | WO2011006803A9 3-0x0-2, 3, -dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition |
| 05/05/2011 | WO2011006794A9 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors |
| 05/05/2011 | WO2011005515A3 Bis-trifluoromethyl honokiol analogs and their use in treating cancers |
| 05/05/2011 | WO2011000811A3 Pharmaceutical solutions for infusion |
| 05/05/2011 | WO2010151076A3 Adjuvant composition comprising (poly-gamma-glutamate)-chitosan nanoparticles |
| 05/05/2011 | WO2010148007A3 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
| 05/05/2011 | WO2010139981A3 Processes for preparing crystalline forms of dasatinib |
| 05/05/2011 | WO2010139979A3 Processes for preparing crystalline forms of dasatinib |
| 05/05/2011 | WO2010138588A9 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 05/05/2011 | WO2010110685A3 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| 05/05/2011 | WO2010099472A8 Spanx-b polypeptides and their use |
| 05/05/2011 | WO2010039997A9 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| 05/05/2011 | WO2009072004A3 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| 05/05/2011 | WO2009072002A3 Bisphenols in cancer therapy |
| 05/05/2011 | WO2009027838A3 Kinamycin f for cancer treatment |
| 05/05/2011 | US20110107443 Novel protein transduction domains derived from secretory leukocyte protease inhibitor |
| 05/05/2011 | US20110107440 Skin cancer associated micrornas |
| 05/05/2011 | US20110106241 Compositions and methods for inhibiting sphingosine kinase |
| 05/05/2011 | US20110105748 Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 05/05/2011 | US20110105747 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| 05/05/2011 | US20110105731 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 05/05/2011 | US20110105721 Peptides |
| 05/05/2011 | US20110105618 Novel modulators of protein kinase signaling |
| 05/05/2011 | US20110105617 Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof |
| 05/05/2011 | US20110105608 Modulators of nuclear receptor co-regulatory protein binding |
| 05/05/2011 | US20110105607 Lipophilic diesters of chelating agent for inhibition of enzyme activity |
| 05/05/2011 | US20110105596 Compositions and methods for prognosis of ovarian cancer |
| 05/05/2011 | US20110105595 Novel promoter and viral vector containing the same |
| 05/05/2011 | US20110105592 Anti-sense microrna expression vectors |
| 05/05/2011 | US20110105591 siRNA COMPOUNDS FOR INHIBITING NRF2 |
| 05/05/2011 | US20110105590 Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
| 05/05/2011 | US20110105589 Apoptosis inducer |
| 05/05/2011 | US20110105588 Compositions comprising notch1 sirna and methods of use thereof |
| 05/05/2011 | US20110105586 Compositions and their uses directed to gemin genes |
| 05/05/2011 | US20110105585 METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF |
| 05/05/2011 | US20110105583 Methods of using mir34 as a biomarker for tp53 functional status |
| 05/05/2011 | US20110105582 Composition for inhibiting function of human flt3 |
| 05/05/2011 | US20110105580 Novel polymorphic forms of sunitinib base |
| 05/05/2011 | US20110105572 Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| 05/05/2011 | US20110105568 Novel method for the production of sulphonylpyrroles as hdac inhibitors |
| 05/05/2011 | US20110105567 Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity |
| 05/05/2011 | US20110105557 Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| 05/05/2011 | US20110105545 GPBP inhibition using Q2 peptidomimetics |
| 05/05/2011 | US20110105544 Carboxylic derivatives for use in the treatment of cancer |
| 05/05/2011 | US20110105542 Pyrazolo--quinazolines |
| 05/05/2011 | US20110105538 Drug response markers |
| 05/05/2011 | US20110105535 Inhibitors of phosphatidylinositol 3-kinase |
| 05/05/2011 | US20110105529 ERCC-1 Gene Expression Predicts Chemotherapy Outcome |
| 05/05/2011 | US20110105527 Pyrazines as delta opioid receptor modulators |